BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» 'Wild' Panel Meeting's Decision Boosts Amevive In Psoriasis Race
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
'Wild' Panel Meeting's Decision Boosts Amevive In Psoriasis Race
June 3, 2002
By
Randy Osborne
No Comments
Hardly had the House passed the Prescription Drug User Fee Act - clearing the way for the next day's approval by the Senate - than all eyes turned from PDUFA to Amevive, Biogen Inc.'s fusion protein for psoriasis. (BioWorld Financial Watch)
BioWorld